Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2017 1
2019 2
2020 5
2021 4
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.
Abou Kors T, Hofmann L, Betzler A, Payer K, Bens M, Truong J, von Witzleben A, Thomas J, Kraus JM, Kalaajieh R, Huber D, Ezić J, Benckendorff J, Greve J, Schuler PJ, Ottensmeier CH, Kestler HA, Hoffmann TK, Theodoraki MN, Brunner C, Laban S. Abou Kors T, et al. Among authors: von witzleben a. Cancer Res Commun. 2024 Feb 28;4(2):571-587. doi: 10.1158/2767-9764.CRC-23-0258. Cancer Res Commun. 2024. PMID: 38329386 Free PMC article.
Regional outcome disparities in German head and neck cancer patients: Shorter survival in Eastern Germany.
Vahl JM, Nagel G, Abou Kors T, Brand M, von Witzleben A, Sonntag M, Grages A, Theodoraki MN, Greve J, Denkinger M, Dallmeier D, Idel C, Stilgenbauer S, Hoffmann TK, Laban S. Vahl JM, et al. Among authors: von witzleben a. Cancer Med. 2023 Dec;12(23):21426-21435. doi: 10.1002/cam4.6690. Epub 2023 Dec 1. Cancer Med. 2023. PMID: 38037808 Free PMC article.
The HLA ligandome of oropharyngeal squamous cell carcinomas reveals shared tumour-exclusive peptides for semi-personalised vaccination.
Mühlenbruch L, Abou-Kors T, Dubbelaar ML, Bichmann L, Kohlbacher O, Bens M, Thomas J, Ezić J, Kraus JM, Kestler HA, von Witzleben A, Mytilineos J, Fürst D, Engelhardt D, Doescher J, Greve J, Schuler PJ, Theodoraki MN, Brunner C, Hoffmann TK, Rammensee HG, Walz JS, Laban S. Mühlenbruch L, et al. Among authors: von witzleben a. Br J Cancer. 2023 May;128(9):1777-1787. doi: 10.1038/s41416-023-02197-y. Epub 2023 Feb 23. Br J Cancer. 2023. PMID: 36823366 Free PMC article.
JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells.
Eschweiler S, Wang A, Ramírez-Suástegui C, von Witzleben A, Li Y, Chee SJ, Simon H, Mondal M, Ellis M, Thomas GJ, Chandra V, Ottensmeier CH, Vijayanand P. Eschweiler S, et al. Among authors: von witzleben a. Cell Rep. 2023 Feb 28;42(2):112040. doi: 10.1016/j.celrep.2023.112040. Epub 2023 Jan 25. Cell Rep. 2023. PMID: 36701231 Free PMC article.
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler S, Ramírez-Suástegui C, Li Y, King E, Chudley L, Thomas J, Wood O, von Witzleben A, Jeffrey D, McCann K, Simon H, Mondal M, Wang A, Dicker M, Lopez-Guadamillas E, Chou TF, Dobbs NA, Essame L, Acton G, Kelly F, Halbert G, Sacco JJ, Schache AG, Shaw R, McCaul JA, Paterson C, Davies JH, Brennan PA, Singh RP, Loadman PM, Wilson W, Hackshaw A, Seumois G, Okkenhaug K, Thomas GJ, Jones TM, Ay F, Friberg G, Kronenberg M, Vanhaesebroeck B, Vijayanand P, Ottensmeier CH. Eschweiler S, et al. Among authors: von witzleben a. Nature. 2022 May;605(7911):741-746. doi: 10.1038/s41586-022-04685-2. Epub 2022 May 4. Nature. 2022. PMID: 35508656 Free PMC article. Clinical Trial.
23 results